John Garrity

For Corporates
Insights into Healthcare M&A: Q3 2024 Trends
Healthcare M&A activity increased in the third quarter of 2024, with 33 transactions vs. 21 in 2023. Healthcare Services was the most active healthcare subsector, representing 42% of deal volume, with the most notable transaction being TowerBrook’s and CD&R’s $8.3B acquisition of R1 RCM. Biopharma transaction volume increased slightly in the third quarter of 2024, with 10 transactions vs. 9 in 2023, while transaction value declined from $13 billion to $9 billion. Oncology was the most active therapeutic area. We expect Biopharma M&A activity to remain dynamic as large biopharmaceutical companies seek to fill revenue and pipeline gaps via acquisitions of development-stage companies. We continue to expect both private and publicly traded pre-commercial biopharma companies to evaluate the full range of strategic alternatives, including partnerships, mergers and sale transactions. Given an improving macroeconomic backdrop and corresponding capital markets environment, we also expect private development-stage private companies to increasingly evaluate IPOs.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Related Team
John Garrity

John Garrity is a Senior Managing Director of Institutional Equities at Leerink Partners.

Mr. Garrity joined the Firm in 1995 as a Vice President and Retail Broker. He has held a variety of roles at the firm including Vice President of Institutional Equities, where he was instrumental in the development of client relationships and building out the Firm’s account base, and Director, where Mr. Garrity facilitated the growth of both the Sales and Equity Research staff. Prior to joining the firm, Mr. Garrity was a Vice President and Retail Broker at Fechtor, Detwiler and Company.

Mr. Garrity earned his B.A. in Marketing from Suffolk University and an M.B.A. in Marketing and Finance from Bentley University.

Partner With Us

Contact Us